Small cell lung cancer (SCLC) trials

AI-generated summary

Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer is being studied. Conditions: Metastatic Solid Cancers, Colorectal Cancer, Breast Cancer +4 • Eligibility: * INCLUSION CRITERIA: * Participants with an appropriate HLA match for available Surgery Branch KRAS TCRs with evaluable metastatic solid cancer (e.g., gastrointestinal, genitourinary, breast, ovarian, non-small cell…. Goal: Background: Many cancer cells produce substances called antigens that are unique to each cancer. These antigens stimulate the body s immune responses. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer is being studied. Conditions: Extensive-stage Small-cell Lung Cancer • Eligibility: Inclusion Criteria: * Have histologically or cytologically confirmed ES-SCLC (using the AJCC \[American Joint Committee on Cancer\] tumor node metastasis staging system combined with Veterans Administration Lung Study…. Goal: This is a Phase III, multisite, randomized, double-blinded study to investigate pumitamig (BNT327) combined with chemotherapy (etoposide/carboplatin) compared to atezolizumab combined with chemotherapy (etoposide/carboplatin) for the treatment of participants with previously untreated extensive-stage small-cell lung cancer (ES-SCLC). Phase/Status/Sponsor: Unknown phase; RECRUITING; BioNTech SE.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer is being studied. Conditions: Advanced Lung Cancer • Eligibility: Inclusion Criteria: * Aged ≥18 years at the time of giving informed consent. * Histological or cytological confirmed unresectable advanced/metastatic lung cancer. Histological classification may be based on…. Goal: This study aims to investigate the combination of BNT324, a B7-H3 antibody-drug conjugate (ADC) with BNT327, a programmed death-ligand 1 (PD-L1) and vascular endothelial growth factor (VEGF) bispecific antibody, in participants with advanced/metastatic or relapsed/progressive small cell lung cancer (SCLC) and non small cell lung cancer (NSCLC). Phase/Status/Sponsor: Unknown phase; RECRUITING; BioNTech SE.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors is being studied. Conditions: Solid Tumor, Advanced Solid Tumor, Solid Tumor, Adult +25 • Eligibility: Inclusion Criteria: \- Must have a pathologically confirmed advanced and unresectable or metastatic solid tumor listed below with documented disease progression on last standard treatment. Part 1 only:…. Goal: The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity to determine the preliminary recommended dose for expansion (RDE) of NKT3964 in adults with advanced or metastatic solid tumors. The goal of the Expansion phase of the study is to evaluate the preliminary anti-tumor activity of NKT3964 at the RDE based on objective response rate (ORR) and determine the preliminary recommended Phase 2 dose (RP2D). Phase/Status/Sponsor: Unknown phase; RECRUITING; NiKang Therapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

BBO-11818 in Adult Subjects With KRAS Mutant Cancer is being studied. Conditions: Non-Small Cell Lung Cancer, NSCLC, PDAC - Pancreatic Ductal Adenocarcinoma +11 • Eligibility: Inclusion Criteria: * Histologically documented locally advanced and unresectable or metastatic NSCLC, PDAC, CRC, or other solid tumor with KRAS G12A, G12C, G12D, G12S, or G12V mutation *…. Goal: A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) is being studied. Conditions: Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer +27 • Eligibility: Inclusion Criteria: * At least 18 years of age or 12 to 17 years of age after Safety Review Committee approval. * Locally advanced or metastatic solid malignancy…. Goal: The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, tolerability and preliminary efficacy of multiple dose levels of rezatapopt as monotherapy and in Phase 1b in combination with pembrolizumab. Phase/Status/Sponsor: Unknown phase; RECRUITING; PMV Pharmaceuticals, Inc.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss is being studied. Conditions: Non Small Cell Lung Cancer, Glioma Glioblastoma Multiforme, Glioma, Malignant +4 • Eligibility: Inclusion Criteria: * Has a tumor with a confirmed MTAP loss * Is ≥18 years of age at the time of signature of the main study ICF *…. Goal: This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific solid tumor types with a confirmed MTAP loss. Phase/Status/Sponsor: Unknown phase; RECRUITING; Tango Therapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The trial tests whether adding pembrolizumab, an immunotherapy drug, to the usual platinum-based chemotherapy after surgery helps people with certain stages of non-small cell lung cancer live longer without the cancer returning. - It is for adults who have had complete surgical removal of stage IIA-IIIB NSCLC (T3-4N2) and who have not received prior systemic treatment for this cancer. - The study compares two timing strategies: pembrolizumab after chemotherapy versus pembrolizumab given at the same time as chemotherapy, to see which approach improves disease-free and overall survival and how it affects side effects and quality of life. - Key eligibility notes include no active autoimmune disease requiring systemic therapy in the past 2 years, no active infection or pneumonitis, not pregnant, and adequate organ function; people with controlled HIV may participate under certain conditions.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors is being studied. Conditions: Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer +6 • Eligibility: Inclusion Criteria: 1. Adult participants must be 18 years of age or older 2. Advanced or metastatic solid tumors excluding primary central nervous system (CNS) tumors 3. For…. Goal: The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161 as a single agent and in combination with pembrolizumab. Phase/Status/Sponsor: Unknown phase; RECRUITING; IDEAYA Biosciences.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

DESTINY-PANTUMOUR04 is being studied. Conditions: Adenocarcinoma (NOS), Anal Cancer, Bladder Cancer +24 • Eligibility: Inclusion Criteria: 1. Adults aged ≥18 years 2. Patients with locally advanced, unresectable, or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment for metastatic…. Goal: This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world setting in the US Phase/Status/Sponsor: Unknown phase; RECRUITING; AstraZeneca.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

LUNG-05: Investigating Chemotherapy Effectiveness for Non-Small Cell Lung Cancer (NSCLC) Metastatic Patients is being studied. Conditions: NSCLC • Eligibility: Inclusion Criteria: * Age ≥ 18 years of age at time of consent * ECOG performance status score of ≤2 * Advanced non-small cell lung cancer to meet…. Goal: This is a Single arm, Simon's two stage pilot study in which patients with Non-Small Cell Lung Cancer (NSCLC) with metastatic disease 2L and beyond will receive OncoChoice-informed chemotherapy following National Cancer Care Network (NCCN) treatment guidelines on dosage and scheduling for NSCLC FDA approved drugs. Phase/Status/Sponsor: Unknown phase; RECRUITING; University of Illinois at Chicago.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer is being studied. Conditions: Non-Small Cell Lung Cancer • Eligibility: Inclusion Criteria: * Histologically or cytologically confirmed diagnosis of locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with documented EGFR Exon 19 deletion or Exon21 L858R…. Goal: Non-small cell lung cancer (NSCLC) is a common type of lung cancer where abnormal cells in the lungs grow out of control. The purpose of this study is to assess adverse events and change in disease activity of telisotuzumab adizutecan compared to standard of care (SOC). Phase/Status/Sponsor: Unknown phase; RECRUITING; AbbVie.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations is being studied. Conditions: Non Small Cell Lung Carcinoma • Eligibility: Inclusion Criteria: * Must have histologically documented non-squamous (NSq) non small cell lung carcinoma (NSCLC) that is locally advanced or metastatic will be enrolled into the study. *…. Goal: Non small cell lung carcinoma (NSCLC) is the most frequently occurring histologic subtype of lung cancer and is the leading cause of cancer-related deaths worldwide. The purpose of this study is to assess adverse events and change in disease activity when Telisotuzumab Adizutecan (ABBV-400) is given in combination with a programmed cell death receptor 1 (PD1) immune checkpoint inhibitor to adult participants to treat NSCLC. Phase/Status/Sponsor: Unknown phase; RECRUITING; AbbVie.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis is being studied. Conditions: Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult +18 • Eligibility: Inclusion Criteria: * Patient must be ≥ 18yrs of age. * Patient must have the ability to understand, and the willingness to sign, a written informed consent form.…. Goal: This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the treatment of patients with radiographically-confirmed progression of Astrocytoma IDH- mutant, Glioblastoma IDH-wildtype, and the safety, pharmacokinetics and efficacy of a repeated dose regimen of NEO212 when given with select SOC for the treatment of solid tumor patients with radiographically confirmed uncontrolled metastases to the brain. The study will have three phases, Phase 1, Phase 2a and Phase 2b. Phase/Status/Sponsor: Unknown phase; RECRUITING; Neonc Technologies, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Circulating Tumor DNA Guided Treatment Monitoring in Advanced Lung Cancer is being studied. Conditions: Non-small Cell Lung Cancer Metastatic • Eligibility: Inclusion Criteria: * Newly diagnosed, histologically verified, Non-Small Cell Lung Cancer (NSCLC) * Advanced or locally advanced disease without curative intended treatment options * Age \> 18 years…. Goal: The study is a prospective randomized interventional study including patients with advanced non-small cell lung cancer, receiving immunotherapy, with the aim of optimizing treatment monitoring. The study aims to investigate the clinical utility of liquid biopsy monitoring in order to reduce the numbers of inefficient treatments and needless toxicity - and to explore the cost-effectiveness and cost-utility of introducing liquid biopsy monitoring in daily clinical practice. Phase/Status/Sponsor: Unknown phase; RECRUITING; Zealand University Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing is being studied. Conditions: Locally Advanced Alveolar Soft Part Sarcoma, Metastatic Alveolar Soft Part Sarcoma, Locally Advanced Non Small Cell Lung Cancer +7 • Eligibility: * INCLUSION CRITERIA: * Participants with a locally advanced or metastatic pathologically confirmed cancer whose NCI Licensed Independent Practitioner (LIP) determined they are candidates for treatment with atezolizumab,…. Goal: Background: A type of drug called monoclonal antibody immune checkpoint inhibitors are often used in cancer treatment. These drugs help the body s immune system fight cancer by blocking proteins that cause cancer cells to grow. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling is being studied. Conditions: Brest Cancer, Lung Cancer (NSCLC), Pancreatic Cancer, Adult +5 • Eligibility: Phase 1 (Common Cancer Early Detection - CCANED) Inclusion Criteria: * Age: Adults aged 40 years or older. * Confirmed diagnosis of one of the following common cancers:…. Goal: The purpose of the CCANED-CIPHER study is to develop and validate an AI-based blood test for early cancer detection and to monitor treatment effectiveness in cancer patients. This two-phase, multi-center observational study aims to identify specific transcriptomic biomarkers in platelets and immune cells that distinguish cancer patients from healthy individuals and correlate with treatment outcomes. Phase/Status/Sponsor: Unknown phase; RECRUITING; Javier Toledo.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers is being studied. Conditions: Advanced Breast Cancer, Advanced Gastric Cancer, Advanced Urothelial Cancer +1 • Eligibility: Inclusion Criteria: 1. Patients must have signed a written informed consent form prior to any trial specific procedures; 2. Patients must be ≥18 years old; 3. Histologically confirmed…. Goal: International study that will evaluate the association of prespecified biomarkers with resistance to Antibody-drug conjugates (ADCs), a type of targeted cancer treatment currently used in clinical practice for treating different tumor types. Phase/Status/Sponsor: Unknown phase; RECRUITING; UNICANCER.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers is being studied. Conditions: Head and Neck Tumors, Kidney Cancers, Small Cell Lung Cancers +3 • Eligibility: * INCLUSION CRITERIA: * Participants must have histopathologically confirmed gastrointestinal neuroendocrine tumors (GI NET), pheochromocytoma/paraganglioma (PPGL), small cell lung cancers (SCLC), kidney cancers (KC), or Head \& Neck…. Goal: Background: Some cancers have high levels of proteins called somatostatin receptors (SSTRs) on the surface of the tumors. These tumors can be in the lung, head and neck, digestive tract, kidneys, and in or near the adrenal glands. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tests GV20-0251 to see if it is safe in adults with advanced or refractory solid tumors. It is a single-center, single-arm early-stage trial at West China Hospital. It uses a 3+3 dose-escalation design, starting with 10 mg/kg and 20 mg/kg given every three weeks, to find a tolerable dose and watch for dose-limiting toxicities. The trial covers multiple solid tumor types to learn about safety and dosing across indications. Key exclusions include active infections, certain heart problems or QT prolongation, autoimmune disease needing immunosuppressive therapy, HIV/HBV/HCV infections, pregnancy, and recent major surgery.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Prediction of Outcome to Neoadjuvant Therapy in Non-small Cell Lung Cancer（NSCLC） is being studied. Conditions: NSCLC, Neoadjuvant Therapy • Eligibility: Inclusion Criteria: 1. pathologically diagnosed non-small cell lung cancer 2. The treatment plan is：receiving neoadjuvant chemo-immunotherapy during the study period, followed by surgical resection Exclusion Criteria: 1. recurrent…. Goal: This observational study aims to construct and validate the performance of a multimodal predictive model in forecasting the outcomes of neoadjuvant therapy in patients with NSCLC. The core research question is: Can a multi-model approach predict outcomes of neoadjuvant therapy for non-small cell lung cancer and provide clinical recommendations? Phase/Status/Sponsor: Unknown phase; RECRUITING; Qian Chu.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors is being studied. Conditions: Cervical Cancer, Breast Cancer, Colon Cancer +4 • Eligibility: 1. Adult participants (age ≥ 18 years old) with any of the following advanced or metastatic solid tumors (documented history of histologically confirmed diagnosis): 1. Metastatic castration-resistant prostate…. Goal: A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or Metastatic GRPR-expressing Tumors Phase/Status/Sponsor: Unknown phase; RECRUITING; Orano Med LLC.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

HC010 in First-line PD-L1 Positive Advanced NSCLC Patients is being studied. Conditions: NSCLC • Eligibility: Inclusion Criteria: * 1\. Voluntarily participate in the study, communicate well with investigators, understand and voluntarily complete the study process according to this protocol, and sign the informed…. Goal: Phase 2 clinical study to evaluate the efficacy, safety, pharmacokinetics and immunogenicity profile of HC010 for injection in patients with positive PD-L1 (TPS ≥1%) Phase/Status/Sponsor: Unknown phase; RECRUITING; HC Biopharma Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer is being studied. Conditions: Previously Treated Non-Small Cell Lung Cancer • Eligibility: 5.1 Registration Step 0: 1. Patients who need the fresh biopsy must also submit whole blood for ctDNA testing (see Section 15.3). These patients must be registered to…. Goal: This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. Phase/Status/Sponsor: Unknown phase; RECRUITING; SWOG Cancer Research Network.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Feasibility Study of Personalized Ultra-fractionated Stereotactic Ablative Radiotherapy (PULSAR) for Cancers of the Central Lung is being studied. Conditions: Cancer, Lung, Metastasis • Eligibility: Inclusion Criteria: 1. Age ≥ 18 years of age. 2. Histologically proven diagnosis of cancer. At a minimum, the lung tumor in consideration for treatment must be clinically…. Goal: The objective of this study is to enhance the safety profile of SAbR in ultra-central tumors of the lung (primary or metastatic) without compromising its effectiveness. Phase/Status/Sponsor: Unknown phase; RECRUITING; University of Texas Southwestern Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry is being studied. Conditions: Cancer, Metastatic, Cancer, Cancer of Pancreas +40 • Eligibility: Inclusion Criteria: * Pts with solid and hematological malignancies; * Pts cancer-related biomarkers, gene variants, fusion and rearrangements (by immunohistochemistry, PCR, FISH or NGS): PD-L1, MSI (MMR), Claudin18.2,…. Goal: International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention. Phase/Status/Sponsor: Unknown phase; RECRUITING; Massive Bio, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors is being studied. Conditions: Melanoma, Medullary Thyroid Cancer, Sinonasal Undifferentiated Carcinoma +8 • Eligibility: Inclusion Criteria: 1. Subject has provided informed consent/assent prior to initiation of any study specific activities/procedures. 2. Subjects ≥ 18 years of age at the time of signing…. Goal: Phase I study to examine safety of the addition of concurrent tarlatamab with standard palliative and consolidative RT regimens , with a main cohort of N=20-24 patients with extracranial anatomic radiation sites. I) After lead in of 10 patients demonstrating safety of treatment, allow for expansion to cranial sites of disease (N=6-10) with continued enrollment in main cohort II) If toxicity criteria is not met in concurrent RT tarlatamab cohort, we will continue with sequential RT, either A) delivered within 7 days prior to cycle 1 day 1, or B) delivered during cycle 1 -2 but with pre- and post-RT washout of 7 days with no drug during RT, to examine safety in a temporally spaced setting. Phase/Status/Sponsor: Unknown phase; RECRUITING; University of Arizona.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of NX-1607 in Adults With Advanced Malignancies is being studied. Conditions: Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer +11 • Eligibility: Key Inclusion Criteria: * Age ≥ 18 years. * Measurable disease per disease-specific response criteria. * Patients must have disease that is metastatic or unresectable and have received…. Goal: This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies. Phase/Status/Sponsor: Unknown phase; RECRUITING; Nurix Therapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Adebrelimab Maintenance Therapy for LS-SCLC Post Induction Chemo-Adebrelimab Plus CRT or CRT Alone is being studied. Conditions: Localized Small Cell Lung Cancer • Eligibility: Inclusion Criteria: 1. Age: 18-75 years old, male or female; 2. Patients with pathologically confirmed localized small cell lung cancer (as defined by the Veterans Administration Lung Study…. Goal: Observation and Evaluation of the Efficacy and Safety of Adalimumab Combined with Chemotherapy Followed by Radiotherapy or Radiotherapy Alone as First-Line Treatment for Limited-Stage Small Cell Lung Cancer Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Peking University Cancer Hospital & Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests LY4066434, a pan-KRAS inhibitor, in people with KRAS-mutant solid tumors. - It includes patients whose tumors have specific KRAS mutations (G12C, G12D, G12V, G12A, G12S, or G13D) and who have locally advanced, unresectable, or metastatic cancer with measurable disease. - The trial will evaluate LY4066434 alone or with other treatments to see if it is safe and tolerable, using two parts: monotherapy dose escalation and dose optimization, over up to about 5 years. - Key exclusions include active CNS metastases, significant cardiovascular disease, active hepatitis B or C or untreated HIV, other active cancers, and uncontrolled infections.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene. is being studied. Conditions: Non-Small Cell Lung Cancer, Sarcoma, Head &Amp; Neck Cancer +2 • Eligibility: Inclusion Criteria: 1. Histologically or cytologically confirmed endometrial, colorectal, head \& neck, non-small cell lung cancer (NSCLC), or sarcoma 2. Patient with progressive, unresectable and/or advanced or metastatic…. Goal: Alterations in the HER2 gene are involved in the development of cancer. These abnormalities are found at highly variable rates (from approximately 2% to 60%) in cancers of the lung, breast, stomach, bile ducts, salivary glands, colon, endometrium, uterus, bladder, bones, blood, etc. Phase/Status/Sponsor: Unknown phase; RECRUITING; UNICANCER.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation. is being studied. Conditions: Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung • Eligibility: Inclusion Criteria: * Histological or cytological diagnosis of advanced, unresectable, and/or metastatic or relapsed/refractory solid tumor. ECOG PS 0 or 1 * Presence of at least 1 measurable…. Goal: The purpose of this study is to learn about the safety and effects of the study medicine alone or when given together with other anti-cancer therapies. This study also aims to find the best dose. Phase/Status/Sponsor: Unknown phase; RECRUITING; Pfizer.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Sigvotatug Vedotin in Advanced Solid Tumors is being studied. Conditions: Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms +9 • Eligibility: Inclusion Criteria: * Disease indication * Participants must have histologically or cytologically confirmed metastatic or unresectable solid malignancy within one of the tumor types listed below (dependent on…. Goal: This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out what its side effects are. Phase/Status/Sponsor: Unknown phase; RECRUITING; Seagen, a wholly owned subsidiary of Pfizer.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Patient and Physician Preference Study in Resectable, Non-small Cell Lung Cancer Treatments is being studied. Conditions: Non-small Cell Lung Cancer (NSCLC) • Eligibility: Inclusion Criteria: Patients * Aged ≥18 years at the time of enrollment in the study * Resident of the US, Germany, or Japan * Able to read, speak,…. Goal: The purpose of this study is to investigate the perspectives and preferences of patients and healthcare professionals (medical oncologists, pneumologists, thoracic surgeons) regarding treatment options in the resectable non-small cell lung cancer (NSCLC) setting Phase/Status/Sponsor: Unknown phase; RECRUITING; Bristol-Myers Squibb.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases is being studied. Conditions: Brain Metastases, Tumor • Eligibility: Inclusion Criteria: Patients are eligible to be included in the study only if all the following criteria apply: 1. Male/female patients who are at least 18 years of…. Goal: This is a single-center, open-label, multi-cohort Phase II study evaluating the efficacy and safety of pembrolizumab in combination with lenvatinib in patients with solid tumors and brain metastases. The study will be comprised of 3 patient cohorts: triple negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), and solid tumor types other than TNBC and NSCLC. Phase/Status/Sponsor: Unknown phase; RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Tool for Improving the Shared Decision-making Process in Patients With Non-small Cell Lung Cancer is being studied. Conditions: Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8 +1 • Eligibility: Inclusion Criteria: * CLINICIANS: * All clinicians within identified departments participating are eligible (doctor of medicine \[MD\]/doctor of osteopathy \[DO\], fellows/residents, physician assistant \[PA\]/nurse practitioner \[NP\]) * PATIENTS:…. Goal: This clinical trial compares the use of a shared decision-making communication tool during a clinical encounter to standard care for improving the quality of the shared decision-making process among patients with non-small cell lung cancer. Lung cancer patients are faced with many decisions about their treatment options. Phase/Status/Sponsor: Unknown phase; RECRUITING; Mayo Clinic.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Purpose of This Study is to Evaluate the Safety, Tolerability and Efficacy of TMT101 Injection Monotherapy in Patients With Advanced Pancreatic Cancer or Non-small Cell Lung Cancer(NSCLC) is being studied. Conditions: Non-small Cell Lung Cancer • Eligibility: Inclusion Criteria: 1. Agrees to follow the trial protocol and visit schedule, has signed informed consent; 2. Subjects must be ≥18 years of age at time of informed…. Goal: This is a first-in-human, single-arm, open-label, dose escalation prospective phase I clinical study to evaluate the Safety, Tolerability and Efficacy of TMT101 Injection Alone in patients with Unresectable, Metastatic or Advanced pancreatic cancer or Non-small Cell Lung Cancer(NSCLC) after Standard Treatment Failure. The primary objective is to evaluate the safety and tolerability of TMT101 Injection as monotherapy in patients with advanced pancreatic cancer and NSCLC, and to determine the recommended therapeutic dose (RD) of TMT101 Injection as monotherapy Phase/Status/Sponsor: Unknown phase; RECRUITING; Peking Union Medical College Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Beta-only IL-2 ImmunoTherapY Study is being studied. Conditions: Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma +34 • Eligibility: Key Inclusion Criteria: 1. Aged at least 18 years (inclusive at the time of informed consent). 2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1.…. Goal: This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; Medicenna Therapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors is being studied. Conditions: Solid Tumors, Advanced Cancer, Renal Cancer +15 • Eligibility: Major Inclusion Criteria: 1. Men and women 18 years of age or older. 2. 9 cohorts will be enrolled: * Cohort A1 / Exon 14 NSCLC MET inhibitor…. Goal: To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CNS tumors harboring MET alterations, solid tumors harboring wild-type MET with overexpression of HGF and MET * efficacy of APL-101 as an add-on therapy to EGFR inhibitor for the treatment of NSCLC harboring EGFR activating mutations and developed acquired resistance with MET amplification and disease progression after documented CR or PR with 1st line EGFR inhibitors (EGFR-I) Phase/Status/Sponsor: Unknown phase; RECRUITING; Apollomics Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Clinical Application Study of PET/CT for Differential Diagnosis of Non-small Cell Lung Cancer is being studied. Conditions: Lung Cancer, Lung Diseases, Lung Neoplasms +2 • Eligibility: Inclusion Criteria: 1. Age 18-80 years; 2. Imaging studies suspecting non-small cell lung cancer; 3. Solid lung nodules (≥8 mm in diameter) diagnosed by chest ct, which are…. Goal: This study aims to explore the efficacy of Trop2, EpCAM-specific PET/CT imaging for noninvasive visualization of Trop2 or EpCAM expression levels in non-small cell lung cancer; and to explore the differences between novel target-specific PET/CT examinations and conventional 18F-FDG PET/CT in the diagnosis and differential diagnosis of solid lung nodules. Phase/Status/Sponsor: Unknown phase; RECRUITING; RenJi Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Spatial Fragmentation Combined With Low-dose Radiotherapy for Immunotherapy Combined With Chemotherapy-resistant Locally Advanced or Advanced Non-small Cell Lung Cancer is being studied. Conditions: Lung Cancers, Radiation Treatment for Tumors • Eligibility: Inclusion Criteria: 1. Sign the informed consent form. 2. Be at least 18 years old. 3. Have a Karnofsky Performance Status (KPS) score of 70 or higher and…. Goal: The purpose of this study was to evaluate the effect of immunotherapy combined with spatial fractionation radiotherapy and low dose radiotherapy on the prognosis of patients with advanced lung cancer under specific dose regimens (spatial fractionation radiotherapy: high dose region: 800-1200cGy × 3f, low dose region: 100-300cGy × 5f; low dose radiotherapy area: 100-300cGy × 5f). Through the phase II clinical trial, to determine the efficacy and safety of the combined treatment model in advanced lung cancer and its effect on the immune microenvironment of patients, so as to provide scientific basis for the optimization of treatment regimen for advanced lung cancer. Phase/Status/Sponsor: Unknown phase; RECRUITING; Tianjin Medical University Cancer Institute and Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Glutamine Plus L. Reuteri Prevents TKI Therapy-diarrhea in Patients With NSCLC is being studied. Conditions: Non-Small Cell Lung Cancer With EGFR Mutation • Eligibility: Inclusion Criteria: * Both sexes * ≥ 18 years old * Pathologically confirmed diagnosis of NSCLC * Stage IIIB - IV by the American Joint Committee of Cancer…. Goal: This open-label randomized clinical trial aims to evaluate the glutamine plus Lactobacillus reuteri supplementation effect in a standard-of-care diet in EGFR mutant patients with advanced non-small cell lung cancer (NSCLC) under tyrosine kinase inhibitors (TKIs) therapy. The main question it aims to answer is ¿What is the effect of glutamine plus L. Phase/Status/Sponsor: Unknown phase; RECRUITING; Instituto Nacional de Cancerologia de Mexico.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors is being studied. Conditions: Solid Tumors, Non-Small Cell Lung Cancer, Colorectal Cancer • Eligibility: Inclusion Criteria: * Males or females aged 18 - 75 years (inclusive). * Histologically confirmed unresectable, recurrent or metastatic solid tumors. * At least one target lesion per…. Goal: HS-20117 is a fully-human EGFR-MET immunoglobulin G1(IgG1)-like bispecific antibody. The purpose of study is to evaluate the safety, tolerability, efficacy, PK profile and immunogenicity of HS-20117 in combination with other drugs in advanced solid tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; Hansoh BioMedical R&D Company.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of DF6215 in Patients with Advanced Solid Tumors is being studied. Conditions: Solid Tumor, Adult, Solid Tumor Cancer • Eligibility: Key Inclusion Criteria * Male or female patients ≥ 18 years old. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * An estimated life…. Goal: A Phase I/Ib, First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of DF6215 Monotherapy and in Combination Therapy in Patients with Advanced (Unresectable, Recurrent, or Metastatic) Solid Tumors; is designed to assess the safety, tolerability, and preliminary efficacy of DF6215 alone or in combination with pembrolizumab in patients with advanced solid tumors. The study is open-label, meaning both participants and investigators are aware of the treatment being administered. Phase/Status/Sponsor: Unknown phase; RECRUITING; Dragonfly Therapeutics.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC). is being studied. Conditions: Extensive Stage Small Cell Lung Cancer (ES-SCLC) • Eligibility: Inclusion Criteria: 1. Diagnosis of small-cell lung cancer (SCLC) (according to WHO classification 2015) confirmed at pathology (histology or cytology). 2. Male or female and ≥ 18 years…. Goal: The goal of this clinical trial is to learn if a combination of atezolizumab and standard chemotherapy works to treat sensitive Extensive-stage Small Cell Lung Cancer, progressing after first-line of treatment. The main questions it aims to answer are: * Does combination of atezolizumab and standard chemotherapy increase overall survival? Phase/Status/Sponsor: Unknown phase; RECRUITING; Gruppo Oncologico Italiano di Ricerca Clinica.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of LP-184 in Patients With Advanced Solid Tumors is being studied. Conditions: Advanced Solid Tumor, Metastatic Solid Tumor, GBM +4 • Eligibility: Patient Inclusion Criteria: 1. ≥18 years of age at the time of consent 2. Provided signed written ICF and voluntary consent prior to any mandatory study-specific procedures, sampling,…. Goal: The primary objective of this study is to evaluate the safety, tolerability, MTD and RP2D of LP-184 in patients with advanced solid tumors who have relapsed from or are refractory to standard therapy or for whom no standard therapy is available. The secondary objectives are to characterize the PK of LP-184 and its metabolites in plasma and assess clinical activity of LP-184. Phase/Status/Sponsor: Unknown phase; RECRUITING; Lantern Pharma Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer is being studied. Conditions: Carcinoma, Non-Small-Cell Lung • Eligibility: Inclusion criteria: * Participant must have histologically or cytologically confirmed metastatic NSCLC characterized by a KRAS G12C mutation at the time of enrollment. For Phase 1: Participant must…. Goal: The main purpose of this study is to find out the most suitable dose (recommended phase 2 combination dose \[RP2CD\]) of amivantamab and olomorasib combination therapy and to assess how well the combination slows down or prevents the growth of tumors in participants with KRAS G12C mutant metastatic non-small cell lung cancer (NSCLC: the most common type of lung cancer; metastatic: has spread to other parts of the body; KRAS G12C mutant: mutation \[change\] in the kirsten rat sarcoma viral oncogene homolog \[KRAS\] gene in tumor cells in which glycine \[G\] at position 12 is replaced with cystine \[C\]). Phase/Status/Sponsor: Unknown phase; RECRUITING; Janssen Research & Development, LLC.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase 1 Study of LNCB74 in Advanced Solid Tumors is being studied. Conditions: Ovarian Cancer, Breast Cancer, Endometrial Cancer +3 • Eligibility: Inclusion Criteria: 1. The participant provides written informed consent 2. ≥ 18 years of age on day of signing informed consent. 3. Participant with histologically or cytologically confirmed…. Goal: This is an open-label, phase 1, dose escalation and dose expansion study to determine safety and tolerability, and to determine the maximum tolerated dose and / or recommended phase 2 dose of LNCB74 in participants with advanced solid tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; NextCure, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

PROspective Master-protocol for Evaluation of Systemic THErapeutics in Elderly With Thoracic Malignancies is being studied. Conditions: Non Small Cell Lung Cancer, Lung Cancer • Eligibility: Inclusion Criteria: * Patient ≥70 years * Non-small-cell lung cancer for which the multidisciplinary consultation required systemic treatment regardless of Tumor-Node-Metastasis (TNM) stage * Patient naïve to systemic…. Goal: The objective of the study is to prospectively generate real-life data in patients aged ≥70 years treated in first line for a thoracic tumor (Non-Small-Cell Lung Carcinoma) according to best standard of care as defined by the European Society for Medical Oncology (ESMO). This cohort will aim to: * characterize participants in terms of geriatrics, biology and carcinology * describe the treatment modalities by stage, as well as the results in terms of efficacy, safety and impact on quality of life. Phase/Status/Sponsor: Unknown phase; RECRUITING; GFPC Investigation.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of MT-4561 in Patients With Various Advanced Solid Tumors is being studied. Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Esophageal Cancer +13 • Eligibility: Main Inclusion Criteria: Patients who have failed at least 1 prior therapy and, who have no standard treatment options demonstrated to provide clinical benefit or who are intolerable…. Goal: This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and efficacy of MT-4561 in patients with advanced solid tumors. This study will be conducted in 3 parts. Phase/Status/Sponsor: Unknown phase; RECRUITING; Tanabe Pharma America, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

BostonGene and Exigent Genomic INsight Study is being studied. Conditions: Breast Cancer, Non-small Cell Lung Cancer, Melanoma +1 • Eligibility: Inclusion Criteria: * Patients must have a confirmed malignancy of: Locally recurrent, unresectable, or metastatic breast cancer or; Unresectable stage III or metastatic non-small cell lung cancer or;…. Goal: The BEGIN Study by BostonGene and Exigent Genomic INsight evaluates the efficacy of comprehensive molecular testing in advanced cancer patients. Using the BostonGene Tumor Portrait test, the study aims to identify actionable findings, assess feasibility, and determine patient enrollment in clinical trials. Phase/Status/Sponsor: Unknown phase; RECRUITING; BostonGene.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer is being studied. Conditions: Unresectable Melanoma, Metastatic Melanoma, Stage III Non-small Cell Lung Cancer +1 • Eligibility: Inclusion Criteria: 1. Participants must have a confirmed diagnosis of Stage IIIC, IIID, or IV unresectable or metastatic melanoma or Stage III or IV NSCLC. 2. Participants who…. Goal: This is a study to investigate the efficacy and safety of an infusion of IOV-4001 in adult participants with unresectable or metastatic melanoma or advanced non-small-cell lung cancer (NSCLC). Phase/Status/Sponsor: Unknown phase; RECRUITING; Iovance Biotherapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

DNA Analysis of Blood and Tissue from Patients with Lung Cancer is being studied. Conditions: Lung Cancer • Eligibility: DISEASE CHARACTERISTICS: * Patient: * Newly diagnosed primary lung cancer * Patient at Massachusetts General Hospital (MGH) or Boston Medical Center Cancer Center PATIENT CHARACTERISTICS: * Not specified…. Goal: RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help the study of cancer in the future. Phase/Status/Sponsor: Unknown phase; RECRUITING; Massachusetts General Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors is being studied. Conditions: Advanced Solid Tumor, Adult Solid Tumor, Adult Disease +5 • Eligibility: Inclusion Criteria: * Males and nonpregnant and non-breastfeeding females, aged ≥ 18 years of age at the time of signing the informed consent. * Subjects with advanced solid…. Goal: The purpose of this study is to test the safety and therapeutic effect of TT125-802 (single agent) in subjects with advanced solid tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; TOLREMO therapeutics AG.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC) is being studied. Conditions: Non Small Cell Lung Cancer • Eligibility: Inclusion Criteria: * Have a full understanding of the study content, process, and possible adverse reactions before the study, and sign the informed consent form (ICF); voluntarily participate…. Goal: The study is being conducted to to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Phase/Status/Sponsor: Unknown phase; RECRUITING; Shanghai Henlius Biotech.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Quantifying Systemic Immunosuppression to Personalize Cancer Therapy is being studied. Conditions: Melanoma, Breast Cancer, Renal Cell Carcinoma +4 • Eligibility: Inclusion Criteria * Histologically documented diagnosis of metastatic/locally advanced melanoma, hormone-refractory breast cancer, RCC and UC, SCCHN, SCC or NSCLC, stage III resectable NSCLC will also be included…. Goal: The Serpentine (Stratify cancER PatiENTs by ImmuNosupprEssion) project, represents the most consistent effort so far attempted to translate MDSC into clinical practise by producing an off-the-shelf compliant assay for quantifying these cells in peripheral blood. Phase/Status/Sponsor: Unknown phase; RECRUITING; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201) is being studied. Conditions: Non-small Cell Lung Cancer (NSCLC) • Eligibility: Inclusion Criteria * Participants must have a histologically- or cytologically-confirmed diagnoses of non-small cell lung cancer (NSCLC) with unresectable Stage III disease. * Participants must have received at…. Goal: A study to evaluate Pumitamig versus Durvalumab following concurrent chemoradiation therapy in participants with unresectable stage III Non-small Cell Lung Cancer (NSCLC) Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Bristol-Myers Squibb.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors is being studied. Conditions: Advanced Solid Tumors • Eligibility: Inclusion Criteria: * Participants have histologically proven advanced solid tumors with known prevalent and high Ly6E expression, Disease characteristic: Participants should have an unresectable locally advanced or metastatic…. Goal: The purpose of this first-in-human (FIH) study is to evaluate the safety, tolerability, Pharmacokinetics (PK), and preliminary clinical activity of M7437 in participants with locally advanced or metastatic solid tumors with known Ly6E expression, including non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), epithelial ovarian carcinoma (EOC), squamous cell carcinoma of the head and neck (SCCHN), pancreatic ductal adenocarcinoma (PDAC), and gastric cancer (GC). Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; EMD Serono Research & Development Institute, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Intratumoral N17350 in Advanced Solid Tumors is being studied. Conditions: Neoplasms, Solid Tumor, Breast Neoplasms, Triple-Negative, Squamous Cell Carcinoma of Skin +4 • Eligibility: Inclusion Criteria: 1. Age ≥18 years (or legal age of consent in the study jurisdiction). 2. Able to provide written informed consent and willing/able to comply with study…. Goal: The goal of this clinical trial is to learn if N17350 works to treat advanced solid tumors in adults. It will also learn about the safety of N17350 and help determine the best dose to use in future studies. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Onchilles Pharma Inc.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Iruplinalkib Tablets as Postoperative Adjuvant Therapy in Stage IA ALK-positive NSCLC With High-risk Factors is being studied. Conditions: NSCLC • Eligibility: Inclusion Criteria: \- 1.Age ≥18 years, male or female. 2.ECOG Performance Status (PS) score: 0-1. 3.Expected survival ≥12 weeks. 4.Histologically or cytologically confirmed non-small cell lung cancer. 5.ALK-positive…. Goal: The primary objective is to evaluate the efficacy and safety of Iruplinalkib Tablets as postoperative adjuvant therapy in patients with stage IA, ALK-positive NSCLC with high-risk factors. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Tianjin Medical University Cancer Institute and Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Molecular Residual, Dynamic Monitoring and Recurrence of Stage III Driver Mutated NSCLC is being studied. Conditions: Non Small Cell Lung Cancer • Eligibility: Inclusion Criteria: 1. Patients with stage III non-small cell lung cancer were confirmed by imaging and histological biopsy 2. Age≥ 18 3. ECOG PS:0-1 4. Tumor molecular testing…. Goal: The goal of this prospective, observational study is to explore the value of dynamic monitoring of minimal residual lesions in driver mutated stage III NSCLC for disease recurrence and prognosis assessment. The main question it aims to answer is: 1\) Whether MRD(Minimal residual disease) status can predict recurrence events in stage III driven-mutant NSCLC in advance Phase/Status/Sponsor: Unknown phase; RECRUITING; Shanghai Chest Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors is being studied. Conditions: Advanced Solid Tumors, Non Small Cell Lung Cancer, Small Cell Lung Cancer • Eligibility: Inclusion Criteria: 1. Age ≥ 18 years old. 2. Inclusion criteria for the study population： Phase 1: Advanced Solid tumors. Phase 2: Extensive-stage SCLC, Non-AGA NSCLC, EGFR mutation…. Goal: This study was designed to evaluate the efficacy and safety of YL201 in combination with Ivonescimab (AK112) in subjects with solid tumor. Phase/Status/Sponsor: Unknown phase; RECRUITING; MediLink Therapeutics (Suzhou) Co., Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors is being studied. Conditions: Clear Cell Renal Cell Cancer (ccRCC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC) +6 • Eligibility: Inclusion Criteria: Part A, B, and C: * Written informed consent, dated and signed by the patient prior to any study-specific procedure. * Part B and C are…. Goal: The main purpose of Part A of the study is to evaluate safety, tolerability and tracer uptake after a single intravenous (IV) administration of \[68Ga\]Ga-DPI-4452 for each tumor type such as clear cell renal cell cancer (ccRCC), pancreatic ductal adenocarcinoma (PDAC), and colorectal cancer (CRC); Part B: is to determine the recommended phase 2 dose (RP2D) \[maximum tolerated dose (MTD) or lower dose\] for \[177Lu\]Lu-DPI-4452 for each tumor type such as ccRCC, PDAC, CRC, and urothelial carcinoma (UC); Part C: is to evaluate the preliminary antitumor activity of \[177Lu\]Lu-DPI-4452 as monotherapy for each tumor type such as ccRCC, PDAC, CRC, and UC; Part D: is to assess the diagnostic concordance between \[68Ga\]Ga-DPI-4452 Positron Emission Tomography (PET) and the histopathology result of the Indeterminate Renal Mass (IDRM); Part E: is to assess \[68Ga\]Ga-DPI-4452 uptake in each tumour type such as UC, muscle invasive bladder cancer (MIBC), head and neck cancer (H\&N), triple negative breast cancer (TNBC), squamous non-small cell lung cancer (NSCLC), and any other tumor with locally confirmed carbonic anhydrase (CA) IX expression except ccRCC, CRC and PDAC. Phase/Status/Sponsor: Unknown phase; RECRUITING; ITM Oncologics GmbH.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Single-arm, Open-label, Phase II Study to Evaluate Efficacy, Safety and Pharmacokinetics of HLX10 + Chemotherapy in Patients With ES-SCLC is being studied. Conditions: SCLC, Extensive Stage • Eligibility: Inclusion Criteria: 1. Voluntary participation in clinical studies; fully understand, be informed about the study and have signed the informed consent form (ICF); willingness to follow and ability…. Goal: Evaluate Clinical Efficacy, Safety and Pharmacokinetics of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) in Combination with Chemotherapy (Carboplatin-Etoposide) in Previously Untreated Japanese Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) Phase/Status/Sponsor: Unknown phase; RECRUITING; Shanghai Henlius Biotech.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests a drug called MGC028 in adults whose ADAM9-expressing solid tumors are relapsed or refractory, unresectable, locally advanced, or metastatic. - It uses dose escalation to find a safe dose and to describe safety and side effects, including any dose-limiting toxicities and the highest dose that can be given safely. - The trial also aims to learn whether MGC028 can shrink tumors, keep cancer from growing, or control disease in these advanced cancers. - Cancers eligible for participation include NSCLC adenocarcinoma, cholangiocarcinoma, colorectal cancer, and pancreatic cancer with specific prior-treatment criteria; key exclusions include active brain metastases, prior ADAM9-targeted therapy, recent major cancer treatment, organ transplant, infection, and pregnancy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors is being studied. Conditions: Solid Tumours, Sarcoma, HNSCC +9 • Eligibility: Inclusion Criteria: 1. Histologically or cytologically confirmed disease, locally advanced or metastatic: For Phase 1a: Solid tumor with a COX2-associated immunosuppressive pathway, for which standard treatment options are…. Goal: The purpose of this study is to investigate the study drug, OKN4395, administered alone and in combination with pembrolizumab. The overall objectives of this study are to determine the safety and tolerability (degree to which side effects of a drug can be tolerated) of OKN4395 alone and in combination with pembrolizumab, OKN4395 and metabolites (broken-down substances) of OKN4395 levels in the blood, and antitumor activity of OKN4395 alone and in combination with pembrolizumab. Phase/Status/Sponsor: Unknown phase; RECRUITING; Epkin.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Perioperative Treatment of Sunvozertinib in Stage II-IIIB NSCLC is being studied. Conditions: NSCLC • Eligibility: Inclusion Criteria: 1. Patients must understand the requirements and content of the clinical trial and provide a handwritten signed and dated informed consent. 2. Age ≥ 18 years…. Goal: This is a single-arm, phase 2 study to investigate the efficacy and safety of sunvozertinib as neoadjuvant and adjuvant treatment for stage II-IIIB non-small-cell lung cancer patients with EGFR exon20 insertion mutation. Phase/Status/Sponsor: Unknown phase; RECRUITING; Tang-Du Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Using Urine Samples to Identify Lung Cancer is being studied. Conditions: Non Small Cell Lung Cancer • Eligibility: Inclusion Criteria: * Phase I (with NSCLC): Aged 18 to 90 years with histologically proven, previously untreated stage I, II, or IIIA NSCLC °Note: Single, monolateral nodule of…. Goal: The researchers are doing this study to test the ability of an animal biosensor platform (ABP) to detect NSCLC. Participants in this study will either be diagnosed with NSCLC, suspected to have NSCLC, or have not been diagnosed or suspected to have NSCLC. Phase/Status/Sponsor: Unknown phase; RECRUITING; Memorial Sloan Kettering Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of Serplulimab Plus Chemotherapy as Neoadjuvant Therapy for Limited-stage Small Cell Lung Cancer (LS-SCLC) is being studied. Conditions: SCLC, Limited Stage • Eligibility: Inclusion Criteria: 1. Voluntarily participate in clinical research and sign written informed consent 2. Male or female patients aged 18-75 years old (including the critical value) 3. Histologically…. Goal: This investigator-initiated, open-label, prospective Phase II clinical trial, planned to take place across multiple centers in China. We aimed to evaluate the efficacy and safety of surgical resection or chemotherapy following serplulimab plus platinum-containing dual induction therapy for stage II-IIIB (N2) LS-SCLC Phase/Status/Sponsor: Unknown phase; RECRUITING; Guangdong Provincial People's Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial) is being studied. Conditions: Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7 • Eligibility: Inclusion Criteria: * Age \>= 18 years * Patients must have undergone complete surgical resection of their stage IB (\>= 4 cm), II or IIIA NSCLC according to…. Goal: This phase III ALCHEMIST treatment trial studies how well nivolumab after surgery and chemotherapy work in treating patients with stage IB-IIIA non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

First in Human Study of QLS5316 in Solid Tumors is being studied. Conditions: Solid Tumors, Colorectal Cancer, Gastric Cancer or Gastroesophageal Junction Adenocarcinoma +2 • Eligibility: Inclusion Criteria: 1. Age ≥ 18 years 2. Eastern Cooperative Oncology Group (ECOG) Performance Status: 0-1 3. Life expectancy ≥ 3 months; 4. Measurable disease per RECIST v1.1…. Goal: This is a first-in-human (FIH) Phase I, multi-center, open-label, study of QLS5316, in patients with advanced solid tumors. The study aim to evaluating the safety, tolerability, preliminary efficacy, pharmacokinetics (PK), and immunogenicity of QLS5316 as monotherapy. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Qilu Pharmaceutical Co., Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Prospective Study of Plasma Genotyping as a Noninvasive Biomarker for Genotype-directed Cancer Care is being studied. Conditions: NSCLC, Melanoma • Eligibility: Inclusion Criteria To participate in this study a participant must meet the eligibility of one of the following cohorts: Cohort 1: Cancers beginning initial treatment * One of…. Goal: Tumor genotyping has become an essential biomarker for the care of advanced lung cancer and melanoma, and is currently used to identify patients for treatment with targeted kinase inhibitors like erlotinib and vemurafenib. However, tumor genotyping can be slow and cumbersome, and is limited by availability of tumor biopsy tissue for testing. Phase/Status/Sponsor: Unknown phase; RECRUITING; Dana-Farber Cancer Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The trial tests impedance cardiography (ICG) to measure heart and blood flow changes during a 6-minute walk test in people with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy and immunotherapy. - It aims to find out whether these cardiac measurements can predict treatment toxicity and survival outcomes. - Participants are adults aged 18 to 75 with untreated, unresectable stage IIIA-IIIC NSCLC and a good performance status. - Key exclusions include mixed histology, pregnancy, life expectancy under 12 weeks, and contraindications to the 6-minute walk test.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Evaluation of Clinical Performance and IVD Test of LifeOS Digital PCR Liquid Biopsy Kits for EGFR T790M Mutation is being studied. Conditions: Non Small Cell Lung Cancer, EGFR T790M • Eligibility: Inclusion Criteria: 1. aged ≥18 years old. 2. Patients with Stage IIIB or IV non-small cell lung cancer (NSCLC) with EGFR mutations. Exclusion Criteria: 1. Pregnant women. 2.…. Goal: Liquid biopsy plays a pivotal role in cancer therapeutics, encompassing critical applications such as early cancer detection, disease progression monitoring, and tailored treatment plan formulation, heralded as a pivotal avenue for the future of cancer management. Established in 2015, LifeOS Genomics Co., Ltd. Phase/Status/Sponsor: Unknown phase; RECRUITING; LifeOS Genomics Corporation.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study on Exploring the Abscopal Effect Induced by Different Radioimmunotherapy Combination Patterns in the Treatment of Non-Small Cell Lung Cancer With Multiple Metastases is being studied. Conditions: NSCLC Stage IV Without EGFR/ALK Mutation • Eligibility: Inclusion Criteria: * Patient must meet all of the following inclusion criteria to be enrolled in this study: 1. Non-small cell lung cancer diagnosed initially through pathological histology.…. Goal: It is planned to carry out a multicenter umbrella study to find the optimal organ combination and the best radioimmunotherapy combination pattern, so as to improve the survival of NSCLC patients with multiple metastases. At the same time, by using multimodal omics data, machine learning will be employed to construct a prediction model for the abscopal effect, and explore the immunoregulation of organ-specific radiotherapy and biomarkers of the abscopal effect. Phase/Status/Sponsor: Unknown phase; RECRUITING; Xinqiao Hospital of Chongqing.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2) is being studied. Conditions: Non-small Cell Lung Cancer • Eligibility: Inclusion Criteria: 1. voluntarily sign a written informed consent to participate in the study and be willing and able to comply with study-related visits and procedures; 2. Male…. Goal: The goal of this clinical trial is to test if PLB1001 works well and safely in Non-small cell lung cancer patients with MET exon 14 mutation. The main questions it aims to answer are: * If it is works well in Non-small cell lung cancer patients with MET exon 14 mutation * If it is safety and tolerant in Non-small cell lung cancer patients with MET exon 14 mutation Participants will 1. Phase/Status/Sponsor: Unknown phase; RECRUITING; Beijing Pearl Biotechnology Limited Liability Company.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

APG-2449 in Patients With Advanced Solid Tumors is being studied. Conditions: Advanced Solid Cancer, Non Small Cell Lung Cancer, Esophageal Cancer +2 • Eligibility: Inclusion Criteria: 1. Dose exploration stage: non-small cell lung cancer diagnosed by histology and/or cytology and positive for ALK/ROS1 gene fusion (molecular diagnosis confirmed by the investigator) and…. Goal: APG-2449 is a novel, orally active, multi-targeted tyrosine kinase inhibitor, which inhibits FAK, ALK, and ROS1 with nanomolar potencies. In preclinical studies, APG-2449 demonstrated potent antiproliferative activity in various cancer cell lines as a single agent. Phase/Status/Sponsor: Unknown phase; RECRUITING; Ascentage Pharma Group Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients is being studied. Conditions: Non-Squamous Non-Small Cell Lung Cancer (NSCLC), Advanced Non Squamous NSCLC • Eligibility: Inclusion Criteria: 1. Male or female ≥18 years of age inclusive, at the time of signing the informed consent. 2. Capable of giving signed informed consent, which includes…. Goal: The goal of this clinical trial is to learn how roginolisib works in combination with dostarlimab with or without docetaxel in adult patients with advanced non small-cell lung cancer. The main questions it aims to answer are: To compare across the treatment arms the proportion of patients with a reduction in Treg cells To evaluate the safety and tolerability of roginolisib plus dostarlimab, with or without docetaxel Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; iOnctura.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Prospective Multicenter Study of the Association Between TCM Syndromes and EGFR-TKI Efficacy in Lung Cancer Patients is being studied. Conditions: Non Small Cell Lung Cancer NSCLC • Eligibility: Inclusion Criteria: * Pathologically or histologically confirmed non-small cell lung cancer (NSCLC) * Age ≥ 18 years * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 *…. Goal: The goal of this observational study is to learn about the relationship between TCM body constitution patterns (called "syndromes") and the effectiveness of EGFR-TKI targeted drugs in patients with lung cancer. Approximately 3000 patients with EGFR-mutant non-small cell lung cancer who are about to start or are already taking EGFR-TKI drugs as part of their regular medical care will be invited to join. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Guangzhou University of Traditional Chinese Medicine.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC) is being studied. Conditions: Lung Cancer, Non-small Cell Lung Cancer • Eligibility: Inclusion Criteria: * Willing and able to provide written informed consent/assent for the trial. * Be ≥ 18 years of age on day of signing informed consent. *…. Goal: The main purpose of this study is to see whether the combination of two drugs called pembrolizumab and vorinostat can help people with advanced lung cancer. Researchers also want to find out if the combination of pembrolizumab and vorinostat is safe and tolerable. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; H. Lee Moffitt Cancer Center and Research Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of IBI363 in Subjects with Advanced Solid Malignancies is being studied. Conditions: Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer +1 • Eligibility: Inclusion Criteria: 1. Subjects have the ability to understand and give written informed consent for participation in this trial, including all evaluations and procedures as specified by this…. Goal: This is a Phase 2, open-label, multicenter study designed to evaluate the efficacy, safety and tolerability of IBI363 (study drug) in subjects with advanced, refractory solid malignancies. Phase/Status/Sponsor: Unknown phase; RECRUITING; Innovent Biologics (Suzhou) Co. Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Clinical Efficacy and Safety of Microwave Ablation Combined With Huaier Granules in Patients With Inoperable Stage IA Non-Small Cell Lung Cancer: A Prospective, Single-Center, Randomized Controlled Clinical Trial is being studied. Conditions: Non-small Cell Lung Cancer (NSCLC), Huaier Granules, Microwave Ablation • Eligibility: Inclusion Criteria Age: ≥ 18 years old. Diagnosis: Histologically or cytologically confirmed IA stage non-small cell lung cancer (NSCLC) that is inoperable. ECOG Performance Status: 0-2 (Eastern Cooperative…. Goal: This prospective, single-center, randomized controlled clinical trial aims to evaluate the efficacy and safety of microwave ablation (MWA) combined with Huaier granules in patients with inoperable stage IA non-small cell lung cancer (NSCLC). A total of 180 eligible patients will be randomly assigned to receive either MWA alone or MWA combined with Huaier granules. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Xin Ye.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Role of MDSCs and Cancer Stem Cells and Their Cross Talks in NSCLC is being studied. Conditions: Lung Neoplasms, Myeloid-Derived Suppressor Cells, Immunosuppression • Eligibility: Inclusion Criteria: * consecutive patients * lung carcinoma surgically treated by surgery only Exclusion Criteria: * patient receiving chemotherapy, radiotherapy or immunotherapy in the neoadjuvant setting (all objectives)…. Goal: Immunotherapy have revolutionized the field of oncology, but response rates are low and all patients relapse, due to cellular and soluble immunosuppressive mechanisms. MDSC are one of the most important immunosuppressive cells, that also harbour non immunologic functions, favouring cancer invasion. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; University Hospital, Bordeaux.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors is being studied. Conditions: Gastric/Gastroesophageal Junction Cancer, Breast Cancer, Colorectal Cancer +3 • Eligibility: Inclusion Criteria: 1. Aged ≥ 18 years (at time of free and informed consent). 2. Participants must have radiographically confirmed progressive disease (PD) during the last treatment prior…. Goal: This is an open-label, multicenter, Phase 1 study to evaluate the safety, tolerability, PK, and preliminary efficacy of KJ015 administered subcutaneously in participants with HER2-expressing solid tumors. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Shanghai Bao Pharmaceuticals Co., Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Radiation-induced Toxicity of the Heart is being studied. Conditions: Non-small Cell Lung Cancer, Esophageal Cancer, Breast Cancer Female • Eligibility: Inclusion Criteria: * Patients 18 years old or older * Patient's consent and written consent is available * Patients with the non-small cell lung cancer or esophageal cancer…. Goal: Late side effects in radio(chemo)therapy \[R(CH)T\] pose a critical limitation to patients' overall survival and quality of life. Even though toxicities of the heart are highly relevant for patients with cancer in the thoracic region, risk stratification models for these toxicities are lacking. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Technische Universität Dresden.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC is being studied. Conditions: Non-squamous Non-small-cell Lung Cancer • Eligibility: Inclusion Criteria: * Signed Informed Consent Form (ICF) * Age ≥ 18 years at time of signing ICF * Ability to comply with the study protocol, in the…. Goal: To evaluate the efficacy of tiragolumab with atezolizumab and bevacizumab in previously-treated advanced non-squamous NSCLC. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Georgetown University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) is being studied. Conditions: Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma +3 • Eligibility: Inclusion Criteria: * Participants must be assigned to S1900E. Assignment to S1900E is determined by the LUNGMAP protocol genomic profiling using the FoundationOne assay. Biomarker eligibility for S1900E…. Goal: This phase II Lung-MAP treatment trial studies the effect of AMG 510 in treating non-squamous non-small cell lung cancer that is stage IV or has come back (recurrent) and has a specific mutation in the KRAS gene, known as KRAS G12C. Mutations in this gene may cause the cancer to grow. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; SWOG Cancer Research Network.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) is being studied. Conditions: Breast Cancer, Cholangiocarcinoma, Colorectal Cancer +13 • Eligibility: Inclusion Criteria: * Histologically- or cytologically-confirmed diagnosis of locally advanced or metastatic solid tumor that harbors an NTRK1/2/3, ROS1, or ALK gene rearrangement * For patients enrolled via…. Goal: This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion. Patients will be assigned to different baskets according to tumor type and gene fusion. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Hoffmann-La Roche.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests Osimertinib plus chemotherapy as the first-line treatment for adults with EGFR mutation-positive NSCLC that is locally advanced or metastatic. - It aims to learn how well this combination works and how safe it is in real-world practice, by looking at investigator-reported progression-free survival and overall survival. - The study is sponsored by AstraZeneca and is currently active but not recruiting. - Eligible participants are adults 18+ with nonsquamous NSCLC and EGFR mutations Ex19del or L858R, at stage IIIB/IIIC or IV, who are considered appropriate for first-line Osimertinib plus chemotherapy by their physician (prior therapies allowed if meeting criteria). - Key exclusions include spinal cord compression or symptomatic brain metastases, a history of interstitial lung disease or active ILD, and other severe uncontrolled conditions.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors is being studied. Conditions: Advanced Solid Tumors • Eligibility: Inclusion Criteria: * Have measurable disease per Response evaluation criteria in solid tumors version 1.1 (RECIST 1.1) as assessed by the local site investigator. * Have an Eastern…. Goal: Researchers are looking for a better way to treat people who have advanced solid tumors. Advanced solid tumors are types of cancer that may have spread to nearby tissue, lymph nodes, and/or to distant parts of the body and that are unlikely to be cured or controlled with currently available treatments. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Bayer.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer is being studied. Conditions: Non Small Cell Lung Cancer, Lung Cancer, Nsclc +2 • Eligibility: Inclusion Criteria: * Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.…. Goal: The purpose of this study is to see if Durvalumab and radiation therapy can delay the worsening of disease in patients with non-small cell lung cancer normally treated with sequential chemotherapy followed by radiation therapy. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Memorial Sloan Kettering Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Real-world Study of Taletrectinib in Advanced ROS1+ NSCLC Following Entrectinib Progression is being studied. Conditions: Non-small Lung Cancer • Eligibility: Inclusion Criteria: * Age ≥ 18 years. * Histologically or cytologically metastatic NSCLC (UICC/AJCC TNM Staging System, 9th Edition, Stage Ⅳ). * At least one measurable target tumor…. Goal: This is a multicenter, non-interventional, observational real-world study to evaluate the efficacy and safety of Taletrectinib in ROS1-positive non-small cell lung cancer (NSCLC) following Entrectinib progression. Patients deemed eligible for Taletrectinib by their physicians were enrolled after providing informed consent. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Innovent Biologics (Suzhou) Co. Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of DXC014 in Patients With Advanced Solid Tumors. is being studied. Conditions: Small Cell Lung Cancer, Melanoma, Prostate Cancer +1 • Eligibility: Inclusion Criteria: 1. Voluntarily sign the informed consent form and comply with the protocol requirements. 2. Male or female. 3. For other solid tumor patients: Age ≥18 years…. Goal: This is a phase I, open-label, first-in-human clinical study designed to evaluate the safety, tolerability, MTD, DLT, RP2D, the PK characteristics, preliminary anti-tumor activity, the immunogenicity of DXC014 in patients with Advanced Solid Tumors. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Hangzhou DAC Biotechnology Co., Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies is being studied. Conditions: Ovarian Cancer, Breast Cancer, Pancreatic Cancer +10 • Eligibility: Key Inclusion Criteria: * Age ≥ 18 at the time of screening * Histological or cytological confirmation of advanced malignancy considered to be suitable for study treatment and…. Goal: This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; AstraZeneca.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase II Study of Platinum (Cisplatin/Carboplatin)and Polymeric Micelles Paclitaxel(Pm-Pac) With Ivonescimab in First Line Metastatic Squamous NSCLC. is being studied. Conditions: Squamous Cell Lung Cancer • Eligibility: Inclusion Criteria: 1. Written informed consent must be signed before implementing any trial-related procedures; 2. Age ≥18 years old; 3. Patients with histologically or cytologically confirmed metastatic or…. Goal: This is a prospective, single-arm, multi-center, phase Ⅱ trial to evaluate the efficacy and safety of Polymeric Micelles paclitaxel(pm-Pac), platinum (cisplatin/carboplatin) in combination with Ivonescimab as first-line treatment in metastatic squamous NSCLC patients. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Jiangsu Cancer Institute & Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors is being studied. Conditions: MSI-H Colorectal Cancer, Melanoma, Anal Carcinoma +28 • Eligibility: Inclusion Criteria: 1. Male/female participants who are at least 18 years of age on the day of signing informed consent with histologically confirmed diagnosis of PD1 mRNA high-expression…. Goal: This is an open-label, parallel group, non-randomized, multicenter phase II study to evaluate the efficacy of spartalizumab (cohorts 1 and 2) and tislelizumab (cohort 3) in monotherapy in patients with PD1-high-expressing tumors. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; SOLTI Breast Cancer Research Group.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Overcoming Resistance to EGFR Neutralization by Combination of Monoclonal Antibodies and Novel Cancer Drugs is being studied. Conditions: Non Small Cell Lung Cancer • Eligibility: Inclusion Criteria: * patients aged ≥ 18 years * patients with advanced cancer characterized by amplification/overexpression or activating mutations of the EGFR receptor. * patients who are candidates…. Goal: The study is aimed at patients with advanced cancer and EGFR mutation. Some molecules recently discovered at the level of tumor tissue can influence the response to anti-EGFR drugs. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; IRCCS Azienda Ospedaliero-Universitaria di Bologna.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Construction of a Prognostic and Prediction Model for Perioperative Immunotherapy in NSCLC: a Multi - Omics Perspective is being studied. Conditions: NSCLC Stage IIIA/B, NSCLC Stage II • Eligibility: Inclusion Criteria: * NSCLC, clinical tumor stage II-IIIB * Without EGFR/ALK gene mutation * Patient 18 years or older. * Scheduled for neoadjuvant immunotherapy. * Eastern Cooperative Oncology…. Goal: This research focuses on exploring biomarkers for the application of PD - 1/PD - L1 immune checkpoint inhibitors in the perioperative immunotherapy of lung cancer. Multi - index tests are conducted on tissues prior to treatment, as well as blood samples at baseline and during the treatment course. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Ziming Li.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors is being studied. Conditions: Non Small Cell Lung Cancer, ROS1-positive Non-Small Cell Lung Cancer (NSCLC) • Eligibility: Inclusion Criteria: 1. Age ≥18 years. 2. Histologically or cytologically confirmed locally advanced or metastatic NSCLC or other solid tumor with documented ROS1 rearrangement. 3. Previously received at…. Goal: The Expanded Access Program will provide an alternate mechanism for these patients, who lack satisfactory therapeutic alternatives and cannot participate in a zidesamtinib clinical trial, to access investigational zidesamtinib. Phase/Status/Sponsor: Unknown phase; AVAILABLE; Nuvalent Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive is being studied. Conditions: Advanced Solid Tumor • Eligibility: Inclusion Criteria: * Immunotherapy naive and without access to approved and/or available immune checkpoint inhibitor (ICI) therapy. * Measurable disease per RECIST v1.1. * One of the following…. Goal: This study is being conducted to determine the safety, tolerability, and preliminary efficacy of INCB099280 in participants with advanced solid tumors. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Incyte Corporation.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors is being studied. Conditions: Solid Tumor, Adult, Epithelial Ovarian Cancer, Small Cell Lung Carcinoma +9 • Eligibility: Key Inclusion Criteria: * Subject has a histologically- or cytologically-diagnosed solid tumor which is advanced or metastatic and which has progressed on or following at least one systemic…. Goal: This is a first-in-human, Phase 1/2 open-label, multicenter, dose-escalation, safety, pharmacokinetics (PK), and biomarker study of CBX-12 in subjects with advanced or metastatic refractory solid tumors. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Cybrexa Therapeutics.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC is being studied. Conditions: Extensive Stage Small Cell Lung Cancer • Eligibility: Inclusion Criteria: Voluntary participation in clinical studies. Male or female aged ≥ 18 years at the time of signing the ICF. Histologically or cytologically diagnosed with ES-SCLC (according…. Goal: This is a randomized, open-label study of Serplulimab plus chemotherapy (Carboplatin-Etoposide) in comparison with Atezolizumab plus chemotherapy in previously untreated US patients with ES-SCLC. Subjects in this study will be randomized to arm A or B at 1:1 ratio as follows: * Arm A (Serplulimab): Serplulimab + chemotherapy (carboplatin-etoposide) * Arm B (control): Atezolizumab + chemotherapy (carboplatin-etoposide) Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Shanghai Henlius Biotech.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors is being studied. Conditions: Advanced Solid Tumor, Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous) +1 • Eligibility: Inclusion Criteria: * Must be ≥18 years of age * Must have histologically or cytologically confirmed diagnosis as follows: 1. Monotherapy Phase 1: A locally advanced unresectable or…. Goal: This is an open-label, dose-exploration and expansion study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of IMM-1-104 when administered as monotherapy or in combination with approved agents in participants with RAS-mutated or RAS/MAPK activated advanced or metastatic solid tumors. The dose exploration will identify the candidate recommended Phase 2 candidate optimal dose of IMM-1-104 to further explore the anti-tumor activity of IMM-1-104 as monotherapy and in combination with approved agents in multiple Phase 2a proof-of-concept cohorts in malignancies of interest. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Immuneering Corporation.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Clinical Study of BT02 in Treating Patients With Advanced Lung Cancer is being studied. Conditions: Advanced Malignant Solid Tumor, Advanced Lung Cancer, Non-Small Cell Lung Cancer +1 • Eligibility: Inclusion Criteria: 1. Patients with pathologically confirmed locally advanced/unresectable or metastatic or recurrent non-small cell lung cancer (NSCLC, according to AJCC TNM staging) and advanced/unresectable limited-stage or extensive-stage…. Goal: The goal of this clinical trial is to assess whether an investigational treatment is safe and tolerable for patients with advanced lung cancer, and to get a preliminary idea of its effectiveness. Participants of all genders, aged between 18 and 75(inclusive), are eligible to join. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Biotroy Therapeutics.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer is being studied. Conditions: Metastatic Colorectal Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Colorectal Cancer AJCC v7 +3 • Eligibility: Inclusion Criteria: * Patients must have histologically or cytologically confirmed non-small cell lung cancer (cohort 1) or colorectal cancer (cohort 2) * Patients must have measurable disease, defined…. Goal: This randomized phase II trial studies the side effects of durvalumab and tremelimumab and to see how well they work with or without high or low-dose radiation therapy in treating patients with colorectal or non-small cell lung cancer that has spread to other parts of the body (metastatic). Immunotherapy with durvalumab and tremelimumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Tumor Associated Neutrophils as a Biomarker of Chemo-immunotherapy Response in Locally Advanced Non-small Cell Lung Cancer : a Model Based on Neoadjuvant Strategy is being studied. Conditions: Non-Small Cell Lung Cancer • Eligibility: Inclusion Criteria: * Age ≥ 18 years. * Resectable non-small cell lung cancer (NSCLC), stage IIA to IIIB. * Lymph node status obtained by Positron Emission Tomoscintigraphy (PET)-scanner,…. Goal: evaluate the predictive value of circulating neutrophil DNA methylation profiles, identified from the ALCINA 2 cohort, on pre-treatment blood samples (T0), for the histological response to neoadjuvant chemo-immunotherapy in patients with resectable non-small cell lung cancer (NSCLC) Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; University Hospital, Montpellier.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is a Phase 1/2 trial testing TC-510, a novel autologous engineered T cell therapy, in adults with advanced cancers that express mesothelin. TC-510 uses T cells modified with a mesothelin-targeting single-domain antibody fused to CD3 and a PD-1:CD28 switch receptor to boost activity against PD-L1–positive cancer cells. Eligible cancers include malignant pleural mesothelioma, serous ovarian adenocarcinoma, pancreatic adenocarcinoma, triple-negative breast cancer, and colorectal cancer, as long as the tumor shows mesothelin expression by immunohistochemistry. Participants must be 18 or older, have 1–5 prior systemic therapies for metastatic or unresectable disease, a good performance status (ECOG 0–1), be fit for leukapheresis, and have adequate organ function; key exclusions are inability to follow study procedures and known non-compliance or drug/alcohol use.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) is being studied. Conditions: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung • Eligibility: Inclusion Criteria: * Has pathologically (histologically or cytologically) confirmed diagnosis of NSCLC * Has Stage IIIA, IIIB, or IIIC NSCLC by American Joint Committee on Cancer Version 8…. Goal: The purpose of this study is to assess the efficacy and safety of pembrolizumab in combination with concurrent chemoradiation therapy followed by either pembrolizumab with olaparib placebo (Arm 1) or with olaparib (Arm 2) compared to concurrent chemoradiation therapy followed by durvalumab (Arm 3) in participants with unresectable, locally advanced NSCLC. Arms 1 and 2 will be studied in a double-blind design and Arm 3 will be open-label. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Merck Sharp & Dohme LLC.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This expanded access program provides ulixertinib (BVD-523) for compassionate use in people with advanced MAPK pathway–altered solid tumors (including KRAS, NRAS, HRAS, BRAF, MEK, and ERK mutations). It is for patients aged 12 and older who have exhausted or not adequately benefited from standard cancer therapies, and it may be given alone or with other tolerable drugs. The goal is to make ULIXERTINIB available and monitor safety and how well patients tolerate it in real-world use. Key exclusions include currently being enrolled in another ulixertinib trial, recent systemic therapy or radiotherapy within defined windows, history of retinal vein occlusion or central serous retinopathy, pregnancy or breastfeeding, significant uncontrolled illness, prior stomach/duodenal surgery affecting absorption, and use of certain interacting medications (strong inhibitors/inducers of CYP1A2, CYP2D6, or CYP3A4).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study in Participants With First-Line Nivolumab Plus Ipilimumb Therapy Combined With Two Cycles of Chemotherapy for Metastatic Non-Small Cell Lung Cancer is being studied. Conditions: Carcinoma, Non-Small-Cell Lung • Eligibility: Inclusion Criteria: * Diagnosis of stage IV Non-Small Cell Lung Cancer (NSCLC) (histologically or cytologically confirmed stage), without known Epidermal Growth Factor Receptor (EGFR)- or Anaplastic Lymphoma Kinase…. Goal: The purpose of the study is to collect real-life data during the early post-market authorization approval period in Germany. The study aims at describing the outcomes, patient characteristics, safety profile, treatment patterns and patient-reported Quality of Life of first-line treatment with nivolumab plus ipilimumab in combination with two cycles of chemo therapy in participants with confirmed stage IV Non-Small Cell Lung Cancer (NSCLC). Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Bristol-Myers Squibb.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of CS1001 in Subjects With Stage IV Non-Small Cell Lung Cancer is being studied. Conditions: Non Small Cell Lung Cancer • Eligibility: Inclusion Criteria: 1. Willing to participate in this trial; fully understand and informed of this trial, and able to provide written informed consent form (ICF). 2. 18-75 years…. Goal: This is a multi-center, randomized, double-blind, phase III study to evaluate the efficacy and safety of CS1001 in combination with platinum-containing chemotherapy versus placebo in combination with chemotherapy in first-line treatment-naive subjects with stage IV non-small cell lung cancer (NSCLC). Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; CStone Pharmaceuticals.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

PET Imaging of Cancer Patients Using 68Ga-DOTA-Siglec-9 is being studied. Conditions: Acute Myeloid Leukemia, Melanoma, Non Small Cell Lung Cancer • Eligibility: Inclusion Criteria: * Diagnosis of acute myeloid leukemia (AML) and fit for allogeneic hematopoietic stem cell transplantation (alloHSCT), as assessed in the standard operating procedures. * Diagnosis of…. Goal: This is a scientific study to determine expression of vascular adhesion protein 1 (VAP-1) in cancer patients by 68Ga-DOTA-Siglec-9 positron emission tomography/computed tomography (PET/CT) before and after cancer treatment. Phase/Status/Sponsor: Unknown phase; ENROLLING_BY_INVITATION; Turku University Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer is being studied. Conditions: Lung Cancer, SCLC • Eligibility: Inclusion Criteria: The patients must satisfy all of the following inclusion/exclusion criteria in order to be eligible for the study: * Must have signed and dated written informed…. Goal: This is an open-label Phase I/II study, with a dose escalation part (Phase I) and a single-arm part (Phase II), in patients with recurrent SCLC who progressed after first-line platinum-based chemotherapy and who are candidates for second line therapy. No PK evaluation is planned in this study as nivolumab and ipilimumab are unlikely to alter plinabulin's PK, since the route of excretion is different. Phase/Status/Sponsor: Unknown phase; COMPLETED; Salma Sabbour.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor is being studied. Conditions: NRG1 Fusion, Pancreatic Cancer, Non Small Cell Lung Cancer +8 • Eligibility: Inclusion Criteria: * Age 18 years or older * At least one evaluable or measurable lesion according to RECIST v1.1 * Patient with advanced metastatic solid tumor with…. Goal: Merus is providing single patient/named access to the HER2/HER3 bispecific antibody, MCLA-128, to patients with advanced NRG1-fusion positive solid tumor under this early access program who are ineligible for an ongoing MCLA-128 clinical trial or have other considerations that prevent access to MCLA-128 through an existing clinical trial. Participating sites will be added as they apply for and are approved for the EAP. Phase/Status/Sponsor: Unknown phase; APPROVED_FOR_MARKETING; Merus B.V..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of Interest of Personalized Radiotherapy Dose Redistribution in Patients With Stage III NSCLC is being studied. Conditions: Non-small Cell Lung Cancer • Eligibility: Inclusion Criteria: * Male or female patients, * Age over 18 years and below 75-year-old, * Good general condition: WHO performance status ≤ 1, * Histological evidence of…. Goal: In patients with locally advanced stage III non-small cell lung cancer, the probability of local control remains low (about 17% at 1 year). Concomitant radio-chemotherapy is the standard treatment. Phase/Status/Sponsor: Unknown phase; COMPLETED; Centre Henri Becquerel.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation is being studied. Conditions: Non Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer +4 • Eligibility: Inclusion Criteria: * Diagnosis of cancer with RET activation, who are not eligible for an ongoing selpercatinib clinical trial and are medically suitable for treatment with selpercatinib *…. Goal: Expanded access for participants with cancer with RET activation who are ineligible for an ongoing selpercatinib (also known as LOXO-292) clinical trial or have other considerations that prevent access to selpercatinib through an existing clinical trial. The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program. Phase/Status/Sponsor: Unknown phase; APPROVED_FOR_MARKETING; Eli Lilly and Company.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The study tests whether people with advanced solid tumors who have stable disease can stop PD-1/PD-L1 treatment after one year without harming outcomes. It is for patients being treated with PD-1/PD-L1 drugs (like pembrolizumab, nivolumab, atezolizumab, durvalumab, or avelumab). Participants are randomly assigned to stop treatment after about one year or continue treatment until the cancer progresses, to learn the best length of therapy. To join, patients must have at least stable disease on scans within six weeks of randomization; those with progressive disease before randomization or immune-related toxicity that prevents staying on therapy beyond one year are excluded.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC is being studied. Conditions: Non-Small-Cell Lung Cancer • Eligibility: Inclusion Criteria: * Patients must have measurable disease. * Age ≥ 18 years * Adequate renal function * Adequate liver function * Adequate hematological function * Have an…. Goal: The objective of this study is to assess safety and efficacy of CAB-AXL-ADC in NSCLC Phase/Status/Sponsor: Unknown phase; COMPLETED; BioAtla, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer is being studied. Conditions: Extensive-Stage Small Cell Lung Cancer • Eligibility: Inclusion Criteria: 1. Patients who sufficiently understand this study and is willing to sign the ICF; 2. Aged from 18 to 75 years (inclusive); 3. Patients with histologically…. Goal: This is an open-label, multi-center Phase II study designed to evaluate the efficacy and safety of Surufatinib plus anti-PD-1/L1 as maintenance therapy after first-line standard of care in patients with ES-SCLC. Phase/Status/Sponsor: Unknown phase; COMPLETED; Hutchison Medipharma Limited.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors is being studied. Conditions: Advanced Solid Tumors, Glioblastoma, Soft Tissue Sarcoma (Excluding GIST) +9 • Eligibility: Inclusion Criteria: 1. Voluntarily signed and dated written informed consent prior to any specific-study procedure. 2. Age ≥ 18 years. 3. Eastern Cooperative Oncology Group (ECOG) performance status…. Goal: Prospective, open-label, dose-ranging, uncontrolled phase I/II study of Lurbinectedin in combination with irinotecan. The study will be divided into two stages: a Phase I dose escalation stage and a Phase II expansion stage. Phase/Status/Sponsor: Unknown phase; COMPLETED; PharmaMar.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007) is being studied. Conditions: Non-small Cell Lung Cancer • Eligibility: Inclusion Criteria: * Has a histologically or cytologically confirmed diagnosis of non-small cell lung cancer (NSCLC) * Has Stage IV NSCLC (American Joint Committee on Cancer \[AJCC 8th…. Goal: The purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combined with lenvatinib (MK-7902/E7080) compared to pembrolizumab alone (with placebo for lenvatinib) in treatment-naïve adults with no prior systemic therapy for their metastatic non-small cell lung cancer (NSCLC) whose tumors have a programmed cell death-ligand 1 (PD-L1) Tumor Proportion Score (TPS) greater than or equal to 1%. The primary study hypotheses are that: 1) the combination of pembrolizumab and lenvatinib is superior to pembrolizumab alone as assessed by Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1); and 2) the combination of pembrolizumab and lenvatinib is superior to pembrolizumab alone as assessed by Overall Survival (OS). Phase/Status/Sponsor: Unknown phase; COMPLETED; Merck Sharp & Dohme LLC.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2) is being studied. Conditions: Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease • Eligibility: Inclusion Criteria: * Histologically confirmed diagnosis of a solid tumor malignancy with KRAS G12C mutation (phase 2 must be either Non-Small Cell Lung Cancer or Colorectal Cancer) *…. Goal: This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 in combination with TNO155 in patients with advanced solid tumors that have a KRAS G12C mutation. Phase/Status/Sponsor: Unknown phase; COMPLETED; Mirati Therapeutics Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study Assessing Risk Factors for Oral Mucositis/Stomatitis and Ocular Surface Events in NSCLC and Breast Cancer is being studied. Conditions: Advanced/Metastatic NSCLC, Advanced/Metastatic HER2-negative Breast Cancer • Eligibility: Inclusion Criteria 1. The inclusion criteria for the NSCLC cohort consists of patients with advanced or metastatic (stage IIIB/IIIC or IV) NSCLC diagnosis between January 1, 2015 and…. Goal: This study will identify risk factors for oral mucositis/stomatitis and ocular surface events (OSE) in patients with advanced/metastatic non-small cell lung cancer (NSCLC) and advanced/metastatic human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Phase/Status/Sponsor: Unknown phase; COMPLETED; Daiichi Sankyo.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers is being studied. Conditions: HER2-expressing Cancers • Eligibility: Inclusion Criteria: * Pathologically-confirmed diagnosis of breast cancer, gastroesophageal adenocarcinoma (GEA), or other HER2-expressing cancer with evidence of locally advanced (unresectable) and/or metastatic disease. * Dose-escalation (Cohort 1):…. Goal: This is a first-in-human, Phase 1, multicenter, open-label, dose-escalation study to establish the maximum-tolerated dose (MTD) or recommended dosage (RD) of ZW49, the investigational agent under study, and to assess the safety and tolerability of ZW49. Eligible patients include those with locally advanced (unresectable) or metastatic HER2-expressing cancers. Phase/Status/Sponsor: Unknown phase; COMPLETED; Zymeworks BC Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study to Evaluate the Safety and Efficacy of Serplulimab Plus Bevacizumab and Chemotherapy in NSCLC Patients With Brain Metastases is being studied. Conditions: Non-small Cell Lung Cancer Stage II, Bevacizumab, Immunotherapy +1 • Eligibility: Inclusion Criteria: * Subjects with stage IV non-squamous non-small cell lung cancer (nsqNSCLC) with brain metastases confirmed by histopathology or cytology; * The patient should provide a gene…. Goal: A multicenter, single-arm, open study to evaluate the safety and efficacy of Serplulimab in combination with bevacizumab and first-line chemotherapy in driver negative non-squamous NSCLC patients with brain metastases Phase/Status/Sponsor: Unknown phase; COMPLETED; Sun Yat-sen University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib is being studied. Conditions: EGFR Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer • Eligibility: Inclusion Criteria: 1. Provision of informed consent prior 2. Patients aged 18 years or older 3. Patients with histological confirmation of locally advanced or metastatic NSCLC 4. Patients…. Goal: A multicentre, open-label, single-arm, molecular profiling study of patients with EGFR mutation-positive locally advanced or metastatic NSCLC treated with osimertinib. Phase/Status/Sponsor: Unknown phase; COMPLETED; AstraZeneca.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Drug Concentration Monitoring of Pembrolizumab in Non-Small Cell Lung Cancer Patients is being studied. Conditions: NSCLC • Eligibility: Inclusion Criteria: * Subjects must be \> 18 years and must voluntary sign an informed consent * Treatment-naïve patients with advanced NSCLC receiving immunotherapy alone (pembrolizumab) or combined…. Goal: This observational study explores associations between drug trough-levels and clinical outcomes in Non Small Cell Lung Cancer (NSCLC) patients treated with immunotherapy (pembrolizumab) either alone or combined with chemotherapy. Through-levels of pembrolizumab will be examined in blood samples collected during the first-line treatment period. Phase/Status/Sponsor: Unknown phase; TERMINATED; Oslo University Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Immunotherapy in Patient With Poor General Condition is being studied. Conditions: Non-small Cell Lung Cancer Stage IV • Eligibility: Inclusion Criteria: 1. Subjects must have signed and dated an IEC (Independent Ethic Committee) approved written informed consent form in accordance with regulatory and institutional guidelines. This must…. Goal: Immunotherapeutic approaches targeting immune checkpoint proteins PD-1/PD-L1 have recently demonstrated clinical efficacy in several cancer types, and have changed the therapeutic landscape in metastatic melanoma or non-small cell lung cancer (NSCLC). The monoclonal anti-PD-1 antibody nivolumab has been registered by both FDA (Food and Drug Administration) and EMA (European Medicine Agency), for metastatic NSCLC patients, after failure of a prior platinum-based chemotherapy. Phase/Status/Sponsor: Unknown phase; COMPLETED; Intergroupe Francophone de Cancerologie Thoracique.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05) is being studied. Conditions: Lung Cancer • Eligibility: Inclusion Criteria: * Histologically or cytologically confirmed diagnosis of stage IV NSCLC without epidermal growth factor receptor (EGFR)-sensitizing mutation, ROS1 and/or anaplastic lymphoma kinase (ALK) translocation. * Measurable…. Goal: The purpose of this study is to evaluate the efficacy and safety of pembrolizumab plus epacadostat compared to pembrolizumab plus placebo as first-line treatment in participants with metastatic non-small cell lung cancer (NSCLC) expressing high levels of programmed cell death ligand 1 (PD-L1). Phase/Status/Sponsor: Unknown phase; COMPLETED; Incyte Corporation.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors is being studied. Conditions: Head and Neck Squamous Cell Carcinoma, Melanoma Excluding Uveal Melanoma, Non-small Cell Lung Cancer, Squamous or Non-squamous +6 • Eligibility: Key Inclusion Criteria: * Part A: Histologically confirmed advanced/metastatic castration-resistant prostate adenocarcinoma, epithelial ovarian cancer, head and neck squamous cell carcinoma, non-small cell lung cancer, urothelial carcinoma, melanoma,…. Goal: The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of intravenous (IV) administration of XmAb808 in combination with pembrolizumab in subjects with selected advanced solid tumors and to identify the minimum safe and biologically effective/recommended dose (RD) and schedule for XmAb808. Phase/Status/Sponsor: Unknown phase; COMPLETED; Xencor, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs is being studied. Conditions: Gynecologic Cancer, Colorectal Cancer, Pancreatic Cancer +7 • Eligibility: Inclusion Criteria: 1. Subjects treated with TCR-T cell drug product on study TCR001-201 or any other Alaunos TCR-T cell drug product study and have either completed their original…. Goal: Long-Term Follow-Up Study for Subjects Enrolled in the Phase I/II Study of Autologous T Cells Engineered using the Sleeping Beauty System to Express T cell Receptors (TCRs) Reactive Against Cancer-specific Mutations in Subjects with Solid Tumors Phase/Status/Sponsor: Unknown phase; COMPLETED; Alaunos Therapeutics.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests CDX-585 in people with advanced solid tumors to find the maximum tolerated dose and to assess safety, tolerability, and signs of effectiveness. - It uses dose-escalation and expansion phases, with an expansion portion studying safety at the chosen dose in selected tumor types. - Eligible participants are patients with recurrent, locally advanced, or metastatic solid tumors who have had standard therapy and have measurable disease. - Key exclusions include severe allergic reactions to monoclonal antibodies, prior anti-ILT4 or anti-PD-1/PD-L1 therapies, active autoimmune disease or pneumonitis, untreated active CNS metastases, recent thrombotic events, or certain other prior cancers.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors is being studied. Conditions: Gynecologic Cancer, Colorectal Cancer, Pancreatic Cancer +9 • Eligibility: Inclusion Criteria: 1. Patients who have completed the HLA Typing and Tumor Neoantigen Identification Protocol (TCR001-002) and for whom a TCR(s) matching the subject's somatic mutation(s) and HLA…. Goal: A Phase I/II study of autologous T cells engineered using the Sleeping Beauty transposon/transposase system to express TCR(s) reactive against neoantigens in subjects with relapsed/refractory solid tumors Phase/Status/Sponsor: Unknown phase; TERMINATED; Alaunos Therapeutics.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors is being studied. Conditions: Solid Tumor • Eligibility: Inclusion Criteria: 1. Advanced solid tumor for which there is no remaining standard curative therapy and no therapy with a demonstrated survival benefit, or they must be ineligible…. Goal: This is a first in human (FIH) 2-part study using ACTM-838 in patients with advanced solid tumors resistant to standard of care treatment. Part 1a will evaluate dose escalation and Part 1b will evaluate dose expansion. Phase/Status/Sponsor: Unknown phase; TERMINATED; Actym Therapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The trial tests whether adding early palliative care to standard oncology care improves quality of life for adults with incurable, advanced lung cancer or non-colorectal GI cancers, compared with standard care alone. - Participants are adults (18+) with confirmed advanced disease not being treated curatively, who were told their disease is incurable within the past 8 weeks, and who are under an oncologist’s care at participating outpatient centers with English reading ability. - Family caregivers who regularly accompany the patient to most visits and have in-person contact at least twice per week can participate. - The main goal is to measure patient-reported quality of life at 12 weeks; secondary goals include other patient and caregiver outcomes and end-of-life care/resource use, plus agreement between patient and caregiver views on prognosis.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer is being studied. Conditions: Acute Myeloid Leukemia, Brain Glioblastoma, Estrogen Receptor Negative +64 • Eligibility: Inclusion Criteria: * Newly diagnosed patients for the following conditions * Colon cancer stage III and IV * Rectal cancer stage II, III, IV * Glioblastoma multiforme (brain)…. Goal: This randomized pilot clinical trial studies health care coach support in reducing acute care use and cost in patients with cancer. Health care coach support may help cancer patients to make decisions about their care that matches what is important to them with symptom management. Phase/Status/Sponsor: Unknown phase; COMPLETED; Stanford University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer is being studied. Conditions: Neoplasms • Eligibility: Inclusion Criteria: * Adult patients aged \>/=18 years, able to provide informed consent and willing to comply with all study procedures. * Histologically confirmed advanced or metastatic solid…. Goal: Determine the safety, tolerability, and maximum tolerated dose (MTD) of IV administered VIP236 as monotherapy in patients with advanced solid tumor cancer Phase/Status/Sponsor: Unknown phase; COMPLETED; Vincerx Pharma, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The study tests Felmetatug Vedotin (SGN-B7H4V), given alone or with pembrolizumab, to see if it is safe and what side effects it may have in people with advanced solid tumors. It is for adults with locally advanced unresectable or metastatic cancers, including certain ovarian/peritoneal cancers, HER2-negative breast cancer, triple-negative breast cancer, endometrial cancer, some lung cancers, cholangiocarcinoma/gallbladder cancer, and adenoid cystic carcinoma. The trial has five parts to find the right dose, assess safety and activity, study the combination with pembrolizumab, and evaluate safety and efficacy in triple-negative breast cancer. Eligibility includes measurable disease and good functioning (ECOG 0–1) with tumor tissue available; key exclusions are a new cancer within 3 years (with some exceptions), active brain metastases, prior MMAE- or B7-H4-targeting therapy, neuropathy ≥ grade 2, or corneal disease. Status: Terminated.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer is being studied. Conditions: Colorectal Cancer, Non-Small Cell Lung Cancer • Eligibility: Inclusion Criteria: * Evaluable or measurable disease per RECIST v1.1 * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Life expectancy of ≥12 weeks…. Goal: The main purpose of the study is to evaluate the safety of GDC-1971 in combination with either osimertinib or cetuximab. The study consists of a dose-finding stage followed by an expansion stage. Phase/Status/Sponsor: Unknown phase; COMPLETED; Genentech, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.